Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Detection and quantification of enzymatically active prostate-specific antigen in vivo.

Ho G, Morin J, Delaney J, Cuneo G, Yared W, Rajopadhye M, Peterson JD, Kossodo S.

J Biomed Opt. 2013 Oct;18(10):101319. doi: 10.1117/1.JBO.18.10.101319.

PMID:
23933968
4.

Novel α(2)β(1) integrin-targeted peptide probes for prostate cancer imaging.

Huang CW, Li Z, Cai H, Shahinian T, Conti PS.

Mol Imaging. 2011 Aug;10(4):284-94. doi: 10.2310/7290.2010.00044. Epub 2011 Apr 1.

PMID:
21486537
5.

Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer.

Thalmann GN, Sikes RA, Chang SM, Johnston DA, von Eschenbach AC, Chung LW.

J Natl Cancer Inst. 1996 Jun 19;88(12):794-801.

PMID:
8637045
6.

PSA-specific and non-PSA-specific conversion of a PSA-targeted peptide conjugate of doxorubicin to its active metabolites.

Wong BK, DeFeo-Jones D, Jones RE, Garsky VM, Feng DM, Oliff A, Chiba M, Ellis JD, Lin JH.

Drug Metab Dispos. 2001 Mar;29(3):313-8.

7.

Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.

Denmeade SR, Sokoll LJ, Dalrymple S, Rosen DM, Gady AM, Bruzek D, Ricklis RM, Isaacs JT.

Prostate. 2003 Mar 1;54(4):249-57.

PMID:
12539223
9.
10.

The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy.

Garsky VM, Lumma PK, Feng DM, Wai J, Ramjit HG, Sardana MK, Oliff A, Jones RE, DeFeo-Jones D, Freidinger RM.

J Med Chem. 2001 Nov 22;44(24):4216-24.

PMID:
11708923
11.

Separation of enzymatically active and inactive prostate-specific antigen (PSA) by peptide affinity chromatography.

Wu P, Stenman UH, Pakkala M, Närvänen A, Leinonen J.

Prostate. 2004 Mar 1;58(4):345-53.

PMID:
14968435
12.
13.

A prostate-specific antigen activated N-(2-hydroxypropyl) methacrylamide copolymer prodrug as dual-targeted therapy for prostate cancer.

Chandran SS, Nan A, Rosen DM, Ghandehari H, Denmeade SR.

Mol Cancer Ther. 2007 Nov;6(11):2928-37.

14.

Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen.

Denmeade SR, Lou W, Lövgren J, Malm J, Lilja H, Isaacs JT.

Cancer Res. 1997 Nov 1;57(21):4924-30.

15.
16.

Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo.

Denmeade SR, Litvinov I, Sokoll LJ, Lilja H, Isaacs JT.

Prostate. 2003 Jun 15;56(1):45-53.

PMID:
12746846
17.

In vivo and in vitro complex formation of prostate specific antigen with alpha 1-anti-chymotrypsin.

Huber PR, Mattarelli G, Strittmatter B, van Steenbrugge GJ, Schmid HP, Maurer A.

Prostate. 1995 Sep;27(3):166-75.

PMID:
7567696
18.

Selective recognition of enzymatically active prostate-specific antigen (PSA) by anti-PSA monoclonal antibodies.

Michel S, Collomb-Clerc E, Geourjon C, Charrier JP, Passagot J, Courty Y, Deléage G, Jolivet-Reynaud C.

J Mol Recognit. 2005 May-Jun;18(3):225-35.

PMID:
15593306
19.

Fluorescent, superparamagnetic nanospheres for drug storage, targeting, and imaging: a multifunctional nanocarrier system for cancer diagnosis and treatment.

Cho HS, Dong Z, Pauletti GM, Zhang J, Xu H, Gu H, Wang L, Ewing RC, Huth C, Wang F, Shi D.

ACS Nano. 2010 Sep 28;4(9):5398-404. doi: 10.1021/nn101000e.

PMID:
20707381
20.

Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.

Katzenwadel A, Schleer H, Gierschner D, Wetterauer U, Elsässer-Beile U.

Anticancer Res. 2000 May-Jun;20(3A):1551-5.

PMID:
10928069

Supplemental Content

Support Center